Bamco Inc. NY bought a new stake in Astera Labs, Inc. (NASDAQ:ALAB – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 500,000 shares of the company’s stock, valued at approximately $37,095,000. Bamco Inc. NY owned 0.32% of Astera Labs at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD bought a new stake in shares of Astera Labs in the first quarter valued at $44,514,000. Alpine Global Management LLC bought a new stake in shares of Astera Labs during the 1st quarter valued at $272,000. Capital World Investors bought a new stake in shares of Astera Labs during the 1st quarter valued at $44,514,000. Capital Research Global Investors bought a new stake in shares of Astera Labs during the 1st quarter valued at $22,257,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Astera Labs during the 1st quarter valued at $1,484,000.
Astera Labs Stock Up 0.2 %
NASDAQ ALAB traded up $0.09 during trading hours on Friday, reaching $47.14. 1,825,349 shares of the stock traded hands, compared to its average volume of 1,360,609. The firm has a 50 day moving average price of $60.96. Astera Labs, Inc. has a 1 year low of $45.41 and a 1 year high of $95.21.
Analyst Upgrades and Downgrades
ALAB has been the topic of a number of analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $85.00 price objective on shares of Astera Labs in a research note on Wednesday, May 8th. JPMorgan Chase & Co. initiated coverage on Astera Labs in a research note on Monday, April 15th. They set an “overweight” rating and a $85.00 price objective on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on Astera Labs in a research note on Monday, April 15th. They set a “buy” rating and a $85.00 price objective on the stock. Barclays started coverage on Astera Labs in a research note on Monday, April 15th. They set an “overweight” rating and a $85.00 price objective on the stock. Finally, Stifel Nicolaus began coverage on Astera Labs in a research report on Monday, April 15th. They set a “buy” rating and a $81.00 target price for the company. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Astera Labs presently has an average rating of “Buy” and an average target price of $86.09.
View Our Latest Analysis on Astera Labs
Astera Labs Company Profile
Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.
See Also
- Five stocks we like better than Astera Labs
- When to Sell a Stock for Profit or Loss
- Is Crypto Cool Again? What Stocks You Should Be Watching
- How to Calculate Options Profits
- Why Call Options Volume for These 2 Stocks Spiked Together
- What is a Special Dividend?
- MarketBeat Week in Review – 7/22 – 7/26
Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALAB – Free Report).
Receive News & Ratings for Astera Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astera Labs and related companies with MarketBeat.com's FREE daily email newsletter.